InvestorsObserver
Sign Up Login

BTX Brooklyn Immunotherapeutics Inc

$0.51 $-0.04 (-6.92%)
Add to Watchlist Compare
Overall

BTX Stock Analysis Overview

What this means: Brooklyn Immunotherapeutics Inc (BTX) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives BTX a rank of 23. Our methodology considers analysis of the company's financial situation and how it has traded recently. BTX rank of 23 means that it ranks below 77% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

BTX Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

BTX Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

BTX Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

BTX Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

BTX Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

BTX Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

BTX Stock Analysis Overview

What this means: Brooklyn Immunotherapeutics Inc (BTX) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives BTX a rank of 23. Our methodology considers analysis of the company's financial situation and how it has traded recently. BTX rank of 23 means that it ranks below 77% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full BTX report

BTX Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

BTX Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

BTX Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

BTX Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

BTX Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

BTX Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Brooklyn Immunotherapeutics Inc (BTX) Analyst Forecast

BTX Price, Volume, Earnings, and Dividend Date

  • Last Price $0.51
  • Previous Close $0.55
  • Change $-0.04
  • Open $0.51
  • Volume 173,371
  • Avg. Volume (100-day) 521,519
  • Market Cap 29,386,666
  • Days Range 0.505 - 0.5495
  • 52-week Range 0.46 - 18.75
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 07/15/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.665
  • PEG Ratio —

Brooklyn Immunotherapeutics Inc (BTX) Company Description

Brooklyn ImmunoTherapeutics Inc is a clinical-stage biopharmaceutical company. It is developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.

Brooklyn Immunotherapeutics Inc (BTX) Stock Chart

View Interactive BTX chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
F-Star Therapeutics Inc (FSTX) (FSTX) $6.24
Trevi Therapeutics Inc (TRVI) (TRVI) $2.56
Allena Pharmaceuticals Inc (ALNA) (ALNA) $0.16
Lexicon Pharmaceutcl (LXRX) (LXRX) $1.88
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $21.36
Chemocentryx Inc (CCXI) (CCXI) $24.44
Chinook Therapeutics Inc (KDNY) (KDNY) $17.54
Altimmune Inc (ALT) (ALT) $11.50
Akouos Inc (AKUS) (AKUS) $4.79
Cogent Biosciences Inc (COGT) (COGT) $8.77